North Star Investment Management Corp. Has $457,000 Stake in GlaxoSmithKline PLC (GSK)

North Star Investment Management Corp. continued to hold its position in shares of GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,605 shares of the pharmaceutical company’s stock at the end of the second quarter. North Star Investment Management Corp.’s holdings in GlaxoSmithKline PLC were worth $457,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in GSK. Pekin Singer Strauss Asset Management IL boosted its position in shares of GlaxoSmithKline PLC by 1.1% in the first quarter. Pekin Singer Strauss Asset Management IL now owns 5,516 shares of the pharmaceutical company’s stock valued at $233,000 after buying an additional 60 shares in the last quarter. Court Place Advisors LLC boosted its position in shares of GlaxoSmithKline PLC by 1.0% in the first quarter. Court Place Advisors LLC now owns 8,481 shares of the pharmaceutical company’s stock valued at $358,000 after buying an additional 84 shares in the last quarter. Park National Corp OH boosted its position in shares of GlaxoSmithKline PLC by 1.9% in the first quarter. Park National Corp OH now owns 6,314 shares of the pharmaceutical company’s stock valued at $266,000 after buying an additional 118 shares in the last quarter. NEXT Financial Group Inc raised its stake in shares of GlaxoSmithKline PLC by 0.9% in the second quarter. NEXT Financial Group Inc now owns 13,396 shares of the pharmaceutical company’s stock valued at $578,000 after buying an additional 118 shares during the last quarter. Finally, Camelot Portfolios LLC raised its stake in shares of GlaxoSmithKline PLC by 0.6% in the first quarter. Camelot Portfolios LLC now owns 20,786 shares of the pharmaceutical company’s stock valued at $876,000 after buying an additional 120 shares during the last quarter. 8.96% of the stock is currently owned by institutional investors.

Shares of GlaxoSmithKline PLC (NYSE:GSK) opened at 42.77 on Friday. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $45.58. The company has a 50 day moving average of $43.28 and a 200 day moving average of $41.70. The stock has a market capitalization of $104.49 billion, a price-to-earnings ratio of 48.60 and a beta of 1.04.

GlaxoSmithKline PLC (NYSE:GSK) last released its earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.62. The firm had revenue of $9.23 billion for the quarter, compared to analyst estimates of $9.09 billion. GlaxoSmithKline PLC had a return on equity of 113.31% and a net margin of 5.48%. Analysts predict that GlaxoSmithKline PLC will post $2.86 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, July 13th. Investors of record on Friday, May 12th were issued a dividend of $0.483 per share. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.93 dividend on an annualized basis and a yield of 4.52%. The ex-dividend date was Wednesday, May 10th. GlaxoSmithKline PLC’s payout ratio is presently 233.74%.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://transcriptdaily.com/2017/07/22/north-star-investment-management-corp-has-457000-stake-in-glaxosmithkline-plc-gsk.html.

Several equities research analysts have commented on the stock. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 13th. Citigroup Inc. lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. ValuEngine lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Berenberg Bank upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $46.00.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply